Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — ABGSC Life Science Summit 2020
22 slides from Cantargia Ab's conference presentation, May 26, 2020
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO May 2020
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value → Potentially more effective treatment against novel target in clinically validated pathway → Right team and clear plan to position our projects and maximize value → First in class platform technology against novel target 3
Slide 4: Cantargia at a glance
Cantargia at a glance Unique immunotherapy antibody CAN04 in phase IIa clinical development Current owners (31 March 2020) ▪ Positive interim data set with response rates higher than historic data ▪ Further phase II milestones during 2020 4th AP fund 7.8% Platform with many potential therapeutic are
Slide 5: Cantargia addresses a huge market
Cantargia addresses a huge market Incidence, Globally 2018 Mortality, Globally 2018 Type of cancer: Type of cancer: Lung: 22,6% Lung: 18,4% Lung cancer Pancreatic cancer Other: Other: 42,9% 35,8% Breast: Breast: 6,6% Incidence 2018 11,6% 2,093,876 458,918 Bowel: (globally) 9,2% Bowel: 10,2% Fraction
Slide 6: Lead antibody CAN04
=a (=) 2 <x (Ss) > mo} ° 2 r=) c © mo} is) ov ar
Slide 7: Validating study – Counteracting tumor inflammation
Validating study – Counteracting tumor inflammation CANTOS trial (n=10,061) Canakinumab phase III trials ▪ Canakinumab (Novartis) ▪ Reduced lung cancer incidence by 67% and death by 77% Adjuvant NSCLC ▪ 1,500 patients ▪ Reduced non-lung cancer death by 37% 3 (CANOPY-A) ▪ After surgery, no mets, plac
Slide 8: CAN04 – Superior MoA against other IL-1 blocking approaches
CAN04 – Superior MoA against other IL-1 blocking approaches Company Compound IL-1α IL-1β ADCC Indication/dev phase • Pancreatic cancer, NSCLC Cantargia CAN04 ++ ++ ++ phase IIa • Autoimmunity, Xbiotech/ Janssen Xilonix ++ – + dermatology • Pancreatic cancer, phase I • Autoimmunity, registered Canaki
Slide 9: Positive phase IIa interim combination data
Positive phase IIa interim combination data On Initiated Evaluable CR/PR SD PD NE therapy → By adding CAN04 response rates are higher than historical data using these standard first line chemo- PDAC 10 7 7 41) 22) 12) therapies alone Historical 23% 27% 20% 30% → 4 of 7 evaluable patients with metast
Slide 10: Combination therapy – Response assessments
Combination therapy – Response assessments Cohort 1 (5 mg/kg) N1 2 4 6 ARM C (NSCLC) N2 2 4 N3 2 4 Months N4 Discontinued after V1 (IRR) Unconfirmed Confirmed Cohort 1 (5 mg/kg) CA19-9 >90% red Progressive disease 2 2 P1 Discountinued after V1 (IRR) P2 2 4 6 8 √ Pseudoprogression 2 2 P3 2 4 6 8 √ P4
Slide 11: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Dec PDAC NSCLC 2018 CANFOUR Q3 Q4 2020 2020 Phase I – Dose escalation Phase IIa – Dosage with assessment with safety assessment of therapeutic effect Monotherapy Combination therapy, NSCLC (Dose group X) Recommended phase II dose Combination therapy, PDAC Dose group 3
Slide 12: Chemotherapy resistance
Chemotherapy resistance → Most chemotherapies induce chemoresistance already after a few months of therapy Ctrl CIS GEM CIS/GEM CIS/GEM + CAN04 2 000 → Several recent studies show chemotherapy induction of IL-1, leading to resistance 1 500 Tumor volume (mm3) → Blocking IL-1 signalling counteracts ch
Slide 13: Pancreatic cancer strategy
Pancreatic cancer strategy Subgroup Share (USA) Treatment Target Resectable 10% Surgery Cure Locally advanced 29% Chemotherapy Response, surgery Metastatic 52% Chemotherapy Response → USA: Estimate 57,000 cases 2019, 5 year survival rate Resectable 34%, Locally advanced 12%, Metastatic 3% → Preparat
Slide 14: CAN04 oncology expansion
c 2 7) c is) a x< oO > Los) 2 ° rs) c ° =a (=) 2 <x (Ss)
Slide 15: IL1RAP in several cancer with high medical need
IL1RAP in several cancer with high medical need IL1RAP Cantargia ▪ Discovery of IL1RAP on cancer cells founded ▪ Antibodies against IL1RAP – antitumor effects 120 based on ▪ IP on antibody therapy against IL1RAP 100 Primary ▪ Non-small cell lung cancer – NSCLC 80 indications ▪ Pancreatic cancer – PD
Slide 16: US phase I clinical trial
US phase I clinical trial → IND granted May 2020, FPI planned Q3 2020 → Combination with checkpoint inhibitor in patients that no longer respond to PD1/PDL-1 therapy → Primary endpoint safety, secondary endpoints include biomarkers and efficacy → Indications include NSCLC, HNSCC and bladder cancer (
Slide 17: Untapped possibilities in autoimmune diseases
Untapped possibilities in autoimmune diseases
Slide 18: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in mouse model → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on s
Slide 19: CAN10 counteract inflammation in disease model
CAN10 counteract inflammation in disease model Total back score Isotype anti-IL-1β mCAN10 Dexamethasone 5 4 → Mechanistic proof of concept for IL1RAP blockade in Score (0-8) 3 inflammatory driven psoriasis model 2 → Effect not dependent on IL-1β blockade 1 0 0 1 2 3 4 5 6 7 Days CAN10 has unique ant
Slide 20: Milestones and summary
> re o S £ S yn me} c © i) oO c ie} _~ n a =
Slide 21: Significant value inflection points
Significant value inflection points Newsflow in 2020 CAN04 → New preclinical data on chemotherapy combinations AACR → Checkpoint combination clinical trial → Phase IIa combination results in PDAC and NSCLC → Phase IIa monotherapy biomarker/biopsy results → Phase IIa expansion of combination therapy
Slide 22: Cantargia at a glance
Cantargia at a glance Unique immunotherapy antibody CAN04 in phase IIa clinical development ▪ Positive interim data set and further phase II milestones during 2020 Platform with many potential therapeutic areas ▪ Cancer and large number of autoimmune/inflammatory diseases Vision of becoming an impor